Coagulation Protein Disorders - 25 Studies Found
Completed |
: Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study) :
: |
Enrolling by invitation |
: A Study of ProMetic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia : Hypoplasminogenemia : 2016-02-12 : Biological: Plasminogen (human) intravenous ProMetic Plasminogen(human) intravenous |
Completed |
: A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency :
: 2014-12-04 : Biological: Plasminogen (Human) Intravenous Plasma-derived purified plasminogen formulated for intraveno |
Recruiting |
: Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products : Hemophilia A : 2016-11-24 :
|
Recruiting |
: A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B :
: 2017-02-14 :
|
Recruiting |
: A Gene Transfer Study for Hemophilia A : Hemophilia A : 2016-12-16 : Genetic: SPK-8011 A novel, bio-engineered, recombinant adeno-associated viral vector carrying human fact |
Terminated |
: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A : Hemophilia A : 2011-09-13 : Biological: OBI-1 intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment |
Completed |
: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A : Hemophilia A : 2010-08-06 : Biological: OBI-1 Intravenous infusion |
Withdrawn |
: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B : Hemophilia B : 2013-11-14 : Biological: IB1001 Prophylaxis (during Treatment and Conti |
Completed |
: BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) :
: 2007-12-21 : Drug: Kogenate (BAY14-2222) One group two treatment schedules, first on-demand then switch to prophylaxi |